Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biomarkers of mRNA vaccine efficacy derived from mechanistic modeling of tumor-immune interactions

12 Jun 2025

Abstract excerpt

The success of mRNA vaccines against infectious diseases such as COVID-19 has opened new avenues for their application in oncology. In cancer immunotherapy, mRNA vaccines-typically encapsulated in lipid nanoparticles (LNPs) 100-200 nm in size-enable delivery of tumor-specific antigens to activate immune responses. Here, we investigated the efficacy of mRNA vaccines in cancer by modeling tumor-immune interactions...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Immunotherapy and Immune Responses
Share to Monoclonal and Polyclonal Antibodies Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40504865
DOI: 10.1371/journal.pcbi.1013163

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biomarkers of mRNA vaccine efficacy derived from mechanistic modeling of tumor-immune interactionsPMID 40504865Read ↗

mRNA Vaccine Platforms and Lipid Nanoparticle Delivery Systems: Molecular Advances, Clinical Breakthroughs, and Regulatory Perspectives (2020–2025)Semantic proximity Read ↗

High-throughput <i>in vivo</i> screening using barcoded mRNA identifies lipid nanoparticles with extrahepatic tropism for cancer immunotherapySemantic proximity Read ↗

Second generation of LNP based mRNA vaccine leads to a T cell–inflamed tumor microenvironment favorable for improving PD-1/PD-L1 blocking therapy and long-term immunity in a cold tumor modelSemantic proximity Read ↗

Intratumoral administration of mRNA COVID-19 vaccine delays melanoma growth in miceSemantic proximity Read ↗

mRNA Vaccine Technology Beyond COVID-19Semantic proximity Read ↗

First-in-human phase I/II, open-label study of mRNA-2416 alone or combined with durvalumab in patients with advanced solid tumors and ovarian cancerSemantic proximity Read ↗

COVID-19 Vaccines: Bolstering Cancer TreatmentSemantic proximity Read ↗

mRNA vaccines as cancer therapiesSemantic proximity Read ↗

Cd73-LNPs promotes antitumor T-cell immunity via amplifying Tlr3-mediated immunostimulatory dendritic cell activationSemantic proximity Read ↗

Coordinated Tuning of Ionizable Lipids and Formulation Redirects mRNA Vaccines Toward Lymphoid-Specific CD4 <sup>+</sup> T Cell ImmunitySemantic proximity Read ↗

mRNA vaccines: a new era in vaccine developmentSemantic proximity Read ↗

Polymer-lipid hybrid nanoparticle enhances mRNA delivery and T cell-mediated immunitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.